$34.38 -0.9 -2.5%
Last Trade - 24/02/21
| Market Cap | ÂŁ406.0m |
| Enterprise Value | ÂŁ318.7m |
| Revenue | ÂŁn/a |
| Position in Universe | 3337th / 6713 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for central nervous system (CNS) disorders. Its product candidate includes dextromethadone (d-methadone), REL-1017, REL-1015 (LevoCap ER), REL-1028 (BuTab) and REL-1021 (MepiGel). d-methadone (dextromethadone, REL-1017) is an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity (NCE) that is being developed for the treatment of central nervous system (CNS) diseases and other disorders. It is also being developed for the treatment of depression, ophthalmological disorders and/or other potential indications. REL-1015 (LevoCap ER) product candidate is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol. REL-1028 is a novel oral formulations of modified release buprenorphine. MepiGel is a topical dosage form of the local anesthetic mepivacaine.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | May 31, 2012 |
| Public Since | March 3, 2014 |
| No. of Shareholders: | 259 |
| No. of Employees: | 6 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 16,241,526 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 880 3rd Ave Fl 12, NEW YORK, 10022-4730, United States |
| Web | https://www.relmada.com/ |
| Phone | +1 646 8763459 |
| Contact | Andrew Ipsum (IR Contact Officer) |
| Auditors | Marcum LLP |
As of 24/02/21, shares in Relmada Therapeutics Inc are trading at $34.38, giving the company a market capitalisation of ÂŁ406.0m. This share price information is delayed by 15 minutes.
Shares in Relmada Therapeutics Inc are currently trading at $34.38 and the price has moved by -25.29% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Relmada Therapeutics Inc price has moved by -39.71% over the past year.
There are no analysts currently covering Relmada Therapeutics Inc.
Relmada Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Relmada Therapeutics Inc does not currently pay a dividend.
Relmada Therapeutics Inc does not currently pay a dividend.
Relmada Therapeutics Inc does not currently pay a dividend.
To buy shares in Relmada Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Relmada Therapeutics Inc are currently trading at $34.38, giving the company a market capitalisation of ÂŁ406.0m.
Here are the trading details for Relmada Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Relmada Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Relmada Therapeutics Inc are currently priced at $34.38. At that level they are trading at 78.14% discount to the analyst consensus target price of 0.00.
Analysts covering Relmada Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.625 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Relmada Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -7.27%. At the current price of $34.38, shares in Relmada Therapeutics Inc are trading at -7.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Relmada Therapeutics Inc.
Relmada Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Relmada Therapeutics Inc based on the size of their shareholding:
